N. Galiè
Pulmonary and Respiratory Medicine · 2001–2020
A researcher in the Science corpus: 28 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 230 citations into it; #736 of 770 by trust here, #26 by citations
Whom N. Galiè trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts N. Galiè overall
Papers from N. Galiè's perspective
Ordered by how strongly the researchers N. Galiè trusts endorse each paper. Same corpus, a different order for every researcher.
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. (Journal of the American College of Cardiology)
- Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (European Respiratory Journal)
- Linear Mixed Models for Longitudinal Data (Technometrics)
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era (Circulation)
- Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. (Annals of Thoracic Surgery)
- Multidetector computed tomography for acute pulmonary embolism. (New England Journal of Medicine)
- Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. (Archives of Internal Medicine)
- Mechanisms of disease: pulmonary arterial hypertension (Nature Reviews Cardiology)
- Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
- Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical… (Annals of Internal Medicine)
Their papers
- Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. (2001) — 703 citations
- Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era (2020) — 789 citations
- Risk stratification and medical therapy of pulmonary arterial hypertension (2019) — 702 citations
- 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. (2016) — 2,875 citations
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2015) — 2,848 citations
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015) — 1,025 citations
- Fibrinolysis for patients with intermediate-risk pulmonary embolism. (2014) — 1,417 citations
- Selexipag for the Treatment of Pulmonary Arterial Hypertension. (2014) — 881 citations
- [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014) — 760 citations
- Pulmonary hypertension due to left heart diseases. (2013) — 608 citations
- Macitentan and morbidity and mortality in pulmonary arterial hypertension. (2013) — 1,290 citations
- Riociguat for the treatment of pulmonary arterial hypertension. (2013) — 1,217 citations
- Tadalafil Therapy for Pulmonary Arterial Hypertension (2009) — 1,037 citations
- Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. (2009) — 808 citations
- Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008) — 596 citations
- Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 (2008) — 1,002 citations
- Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2008) — 2,605 citations
- Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). (2008) — 785 citations
- Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. (2008) — 925 citations
- Survival with first-line bosentan in patients with primary pulmonary hypertension (2005) — 617 citations